Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.32 |
| ▸ | EIF4EBP1 | Q13541 | 8/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | LTC4S | Q16873 | 2/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.31 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11922596 | 0.93 | SCN9A (0.33) | SCN9AGPBAR1MRGPRX4P2RX3 | |
| SCHEMBL11991482 | 0.93 | SCN9A (0.32) | SCN9AEIF4EBP1LTC4SGPBAR1 | |
| SCHEMBL11922631 | 0.91 | GRM2 (0.30) | — | |
| SCHEMBL11922615 | 0.88 | SCN9A (0.34) | SCN9ATRPM8LTC4SMRGPRX4 | |
| SCHEMBL13044776 | 0.86 | HDAC8 (0.33) | SCN9ATRPM8GPBAR1 | |
| SCHEMBL13044759 | 0.85 | HDAC8 (0.34) | SCN9ATRPM8GPBAR1 | |
| SCHEMBL13044775 | 0.85 | GAA (0.34) | SCN9ALTC4SGPBAR1MRGPRX4 | |
| SCHEMBL11991501 | 0.85 | EIF4EBP1 (0.32) | EIF4EBP1LTC4S | |
| SCHEMBL13044761 | 0.85 | PTGER1 (0.32) | SCN9A | |
| SCHEMBL11992939 | 0.84 | MET (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242140-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-14 | — | — | US | disclosed |
| US-8242140-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-14 | — | — | US | disclosed |
| US-20100190779-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| US-20100190779-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| WO-2009018657-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190779-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2H, POLR2E | SCN9A 2265/4885EIF4EBP1 1549/4885TRPM8 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.